Japanese clinical development company Alpha Fusion Inc and Curadh MTR Inc, a US-based biotechnology research firm, announced on Monday plans to enter a strategic partnership, including a joint venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals.

This collaboration combines Alpha Fusion's experience in At-211 drug discovery and early clinical work in Japan, with Curadh's global expertise in radiopharmaceutical development.

The joint venture will focus on clinical development of lead products in the United States as well as broadly developing a pipeline of At-211 products. The partners announced their plans at the World Astatine Community Meeting.